Alnylam Pharmaceuticals, Inc. Message Board
-
FDA FastTrack for RSV Therapeutic
RNAi therapeutics are revolutionary within the methodology of there success, following a successful Phase I of Alnylam Pharmaceuticals RSV candidate what here is everyone thoughts on seeking FDA FastTrack status �. Thoughts here??? Toxicology and efficieny throughout preclinical data, with EVERY DRUG investigated, has thus far been AMAZING
-
You may read, but you can't write. You should proof read your statements before patting yourself on the back so much. Meticulously educated?? I personally believe ALNY has the possibility to become a life changing(financially)stock. Seldom, if at all, do you find a diamond in the rough in it's early phase. This company is on the cutting edge of something huge, RNAI. I don't have all my eggs in one basket, but I am wighted pretty heavy in this one.
Good luck to all! -
UTHR is the correct symbol not UTHR.
-
Jewell ALNY is easy.Take a look at Virexx-VIR on the Toronto.Pay special attention to the caliber of the scientist and their Phase III ovarian cancer drug Ovarex-United Therapeutics (UTP) is their partner.
-
Fast track not important. Adverse events and proof of concept most interesting. And this will take some time.
Meanwhile new partnerships will be the main driver. -
What a finish, eh? Don't know about fast-track status. As it is one of the first human clinical trials with this type of therapeutic, it would be tough, in my opinion - especially since it is for RSV. If it was for pandemic flu, perhaps we could get fast-track approval.
- 1 Reply to jaqueitch
-
To get fast track status their has to be a pressing need. RSV doesn't fit the bill. More to the point, this is a proof of principle clinical trial. I doubt managment would even apply for it. If safety is a problem, and by targeting RSV as number 1 trial they're hedging, fast track could kill this company. Glad I'm in though!!
-
Certainly glad I am in on this one. Definately worth the wait.
-